Durability of platelet counts during 24-week double-blind period
| No. of weeks with platelet count (in the absence of rescue therapy) . | All patients . | Responders∗ . | ||||
|---|---|---|---|---|---|---|
| Rilzabrutinib . | Placebo . | P value . | Rilzabrutinib . | Placebo . | P value . | |
| 50 × 109/L or between ≥30 × 109/L and <50 × 109/L and at least doubled from baseline | n = 133 | n = 69 | n = 85 | n = 23 | ||
| LS mean (SE) | 7.18 (0.75) | 0.72 (0.35) | <.0001 | 11.40 (0.99) | 2.57 (0.86) | <.0001 |
| LS mean difference (SE) vs placebo 95% CI | 6.46 (0.78) 4.92-7.99 | 8.83 (1.08) 6.72-10.93 | ||||
| ≥30 × 109/L and at least doubled from baseline | n = 133 | n = 69 | n = 84 | n = 23 | ||
| LS mean (SE) | 6.95 (0.75) | 0.64 (0.34) | <.0001 | 11.20 (1.01) | 2.38 (0.86) | <.0001 |
| LS mean difference (SE) vs placebo 95% CI | 6.31 (0.78) 4.79-7.83 | 8.81 (1.08) 6.71-10.92 | ||||
| No. of weeks with platelet count (in the absence of rescue therapy) . | All patients . | Responders∗ . | ||||
|---|---|---|---|---|---|---|
| Rilzabrutinib . | Placebo . | P value . | Rilzabrutinib . | Placebo . | P value . | |
| 50 × 109/L or between ≥30 × 109/L and <50 × 109/L and at least doubled from baseline | n = 133 | n = 69 | n = 85 | n = 23 | ||
| LS mean (SE) | 7.18 (0.75) | 0.72 (0.35) | <.0001 | 11.40 (0.99) | 2.57 (0.86) | <.0001 |
| LS mean difference (SE) vs placebo 95% CI | 6.46 (0.78) 4.92-7.99 | 8.83 (1.08) 6.72-10.93 | ||||
| ≥30 × 109/L and at least doubled from baseline | n = 133 | n = 69 | n = 84 | n = 23 | ||
| LS mean (SE) | 6.95 (0.75) | 0.64 (0.34) | <.0001 | 11.20 (1.01) | 2.38 (0.86) | <.0001 |
| LS mean difference (SE) vs placebo 95% CI | 6.31 (0.78) 4.79-7.83 | 8.81 (1.08) 6.71-10.92 | ||||
Responders included patients who achieved the platelet count threshold being measured.